It was a tough month for biopharmaceutical companies as a combination of clinical trial failures and drug pricing rhetoric ramping up in Washington kept investors sitting on their hands. As a result, the BioWorld Biopharmaceutical Index fell more than 6 percent in value, underperforming the general markets, with the Dow Jones Industrial Average closing March just below water and the Nasdaq Composite index recording an almost 2 percent gain in the same period.